Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells
Authors
Keywords
Pancreatic cancer, Slug, CD133, Chemoresistance, Gemcitabine
Journal
Human Cell
Volume 28, Issue 4, Pages 167-174
Publisher
Springer Nature
Online
2015-05-21
DOI
10.1007/s13577-015-0117-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis
- (2014) Qiang Ding et al. Molecular Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells
- (2013) Daisuke Tamura et al. Cancer Medicine
- EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
- (2012) Alexandria M Haslehurst et al. BMC CANCER
- Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy
- (2012) Sonshin Takao et al. Journal of Hepato-Biliary-Pancreatic Sciences
- MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms
- (2012) Y-N Liu et al. ONCOGENE
- A Novel Network Integrating a miRNA-203/SNAI1 Feedback Loop which Regulates Epithelial to Mesenchymal Transition
- (2012) Michèle Moes et al. PLoS One
- Regulatory coordination of clustered microRNAs based on microRNA-transcription factor regulatory network
- (2011) Jin Wang et al. BMC Systems Biology
- Comprehensive patterns in microRNA regulation of transcription factors during tumor metastasis
- (2011) G. Reshmi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial–mesenchymal transition in pancreatic cancer
- (2011) Qiang Ding et al. Human Cell
- Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells
- (2010) Manuela Mancini et al. CELLULAR SIGNALLING
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
- (2009) Z. Wang et al. CANCER RESEARCH
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- Biomarkers for epithelial-mesenchymal transitions
- (2009) Michael Zeisberg et al. JOURNAL OF CLINICAL INVESTIGATION
- Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells
- (2009) Nawneet K. Kurrey et al. STEM CELLS
- CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer
- (2008) S Maeda et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Double-Negative Feedback Loop between ZEB1-SIP1 and the microRNA-200 Family Regulates Epithelial-Mesenchymal Transition
- (2008) C. P. Bracken et al. CANCER RESEARCH
- Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma
- (2008) Paras Jethwa et al. WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started